1279028-30-6

Basic information

• Product Name: tert-butyl [2-(methyl{3-[2-(morpholin-4-yl)pyrimidin-5-yl]benzyl}amino)-2-oxoethyl]carbamate
• Synonyms: tert-butyl [2-(methyl{3-[2-(morpholin-4-yl)pyrimidin-5-yl]benzyl}amino)-2-oxoethyl]carbamate
• CAS NO: 1279028-30-6
• Molecular Weight: 441.53
• Mol File: 1279028-30-6.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: tert-butyl [2-(methyl{3-[2-(morpholin-4-yl)pyrimidin-5-yl]benzyl}amino)-2-oxoethyl]carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl [2-(methyl{3-[2-(morpholin-4-yl)pyrimidin-5-yl]benzyl}amino)-2-oxoethyl]carbamate(1279028-30-6)
• EPA Substance Registry System: tert-butyl [2-(methyl{3-[2-(morpholin-4-yl)pyrimidin-5-yl]benzyl}amino)-2-oxoethyl]carbamate(1279028-30-6)

Safety Data

• Hazardous Substances Data: 1279028-30-6(Hazardous Substances Data)

Upstream product

• 957198-30-0 4-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl]morpholine 
• 1279027-03-0 tert-butyl {2-[(3-bromobenzyl)(methyl)amino]-2-oxoethyl}carbamate 

Relevant articles and documents

Synthesis and pharmacological evaluation of glycine amide derivatives as novel vascular adhesion protein-1 inhibitors without CYP3A4 and CYP2C19 inhibition

Vascular adhesion protein-1 (VAP-1) is a promising therapeutic target for the treatment of diabetic nephropathy. Here, we conducted optimization studies of our lead compound 1, which we previously reported as a novel VAP-1 inhibitor, to enhance the inhibition of human VAP-1 and to reduce CYP3A4 and CYP2C19 inhibition. As a result, we identified 3-chloro-4-{4-[5-(3-{[glycyl(methyl)amino]methyl}phenyl)pyrimidin-2-yl]piperazin-1-yl}benzoic acid (17h) as a novel orally active VAP-1 inhibitor, with 14-fold increased human VAP-1 inhibitory activity compared to 1, without CYP3A4 and CYP2C19 inhibition. Oral administration of 17h significantly inhibited the progression of proteinuria in streptozotocin (STZ) induced diabetic rats at 0.3 and 1?mg/kg, suggesting that this compound has potential to be a therapeutic agent for the treatment of diabetic nephropathy.